News | July 30, 2008

Cath Labs Turn Patients Away if They are Too Obese

July 31, 2008 – A survey of cardiovascular catheterization laboratories in the U.S. found obese patients who weigh more than the cath lab’s equipment limits are referred to other facilities at 22 percent of those surveyed, but 70 percent could not answer the question.

The telephone survey results were published this week in the Aug. 1 issue of the American Journal of Cardiology.

The survey was performed to determine the current weight limits of 94 cath labs in the U.S. The minimum weight limit was 350 pounds, the mean limit was 437.5 pounds, and maximum weight limit was 550 pounds.
If a patient does exceed the weight limit of the cath lab’s table, 21 facilities said they referred the patient to other institutions. However, 66 respondents could not provide an answer. The survey showed in this population, 5.2 ± 3.4 patients/hospital/year were rejected for being over the weight limit.

The authors, Thomas E. Vanhecke, M.D., Aaron D. Berman, M.D., Peter A. McCullough, M.D., MPH, of the division of cardiology, department of internal medicine, William Beaumont Hospital, Royal Oak, MI, hope the results provide useful information for the future management of the growing obese population.

For more information: www.ajconline.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now